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Rationale 
Accumulating evidence indicates that the mixed serotonin and dopamine receptor agonist 
lysergic acid diethylamide (LSD) induces an altered state of consciousness that resembles 
dreaming.  
 
Objectives 
To test the hypotheses that LSD produces dreamlike waking imagery, and that this imagery 
depends on 5-HT2A receptor activation and is related to subjective drug effects.  
 
Methods 
Twenty-five healthy subjects performed an audio-recorded guided mental imagery task 7 h 
after drug administration during three drug conditions: placebo, LSD (100 mcg orally) and 
LSD together with the 5-HT2A receptor antagonist ketanserin (40 mg orally). Cognitive 
bizarreness of guided mental imagery reports was quantified as a standardised formal measure 
of dream mentation. State of consciousness was evaluated using the Altered State of 
Consciousness (5D-ASC) questionnaire. 
 
Results 
LSD, compared with placebo, significantly increased cognitive bizarreness (p < 0.001). The 
LSD-induced increase in cognitive bizarreness was positively correlated with the LSD-
induced loss of self-boundaries and cognitive control (p < 0.05). Both LSD-induced increases 
in cognitive bizarreness and changes in state of consciousness were fully blocked by 
ketanserin. 
 
Conclusions  
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LSD produced mental imagery similar to dreaming, primarily via activation of the 5-HT2A 
receptor and in relation to loss of self-boundaries and cognitive control. Future 
psychopharmacological studies should assess the differential contribution of the D2/D1 and 5-
HT1A receptors to cognitive bizarreness. 
 
 
Keywords: LSD, ketanserin, 5-HT2A receptor, guided mental imagery, dreams, cognitive 
bizarreness, healthy subjects, self-boundaries and cognitive control, visual hallucinations 
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Introduction 
The effects of serotonergic or classic psychedelics such as the semisynthetic lysergic acid 
diethylamide (LSD) share distinct phenomenological similarities with night sleep dreaming, 
such as vivid sensorimotor imagery, alterations in thought processes, disinhibition of basic 
emotions and needs, and changes in the feeling and control of the self (Hobson 2001, 
Fischman 1983, Jacobs 1978, Savage 1955).  
 
The notion that psychedelics produce a dreamlike state in humans is supported by 
phenomenological, neurophysiological and pharmacological evidence. Early research with 
LSD showed that the drug increased saccadic eye movements and early rapid-eye movement 
(REM) dream phases when administered during sleep or shortly before sleep onset (Green 
1969, Torda 1968, Muzio et al. 1966). Patients undergoing LSD-/psilocybin-assisted 
psychotherapy (Leuner 1981, Chandler and Hartman 1960) and healthy subjects that were 
administered LSD or psilocybin in an experimental setting (Carhart-Harris et al. 2016, 
Schmid et al. 2015, Studerus et al. 2011, Abramson et al. 1955) rated the overall quality of the 
psychedelic-induced subjective experience as a dreamlike state that included the experience of 
facilitated access to memories of the past and fantasies about the future. Neuroimaging studies 
showed that, in psychedelic states (Lebedev et al. 2015, Tagliazucchi et al. 2014, Carhart-
Harris and Nutt 2014) and REM dreams (Solms 2000, Braun 1997, Maquet et al. 1996), and 
following direct electrical stimulation of the temporal lobe (Mégevand et al. 2014, Halgren et 
al. 1978), dreamlike experiences such as visual hallucinations and psychotic-like alterations in 
the sense of self correlated with increases in neuronal activation of temporal lobe regions. 
However, the highly variable phenomenological content of psychedelic imagery has so far 
undermined endeavours to show a stringent link between the psychedelic-induced state of 
consciousness and dreaming.  
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Dreaming is defined as mental activity characterised by vivid, predominantly visual, imagery 
that follows a narrative structure and occurs during sleep (Nir and Tononi 2010). Extensive 
studies on the basic phenomenological structure of dreaming showed that cognitive 
bizarreness is a common feature of the formal organisation of dream mentation, and can be 
operationalised and validly assessed as an index of dream state (Hobson 2009). Cognitive 
bizarreness is the strange, irrational and fanciful quality of REM sleep dream mentation, 
which is characterised by the presence of improbable or impossible imaginary events, 
characters, objects, thoughts or feelings (Hobson 2009). The principal aim of this study was to 
use cognitive bizarreness as a measure of dreamlike imagery to test the hypothesis that LSD 
produces dreamlike waking imagery. Moreover, given that both LSD and dreaming induce 
changes in a range of subjective experiences, including perception, mood, cognition and sense 
of self, we further aimed to assess the relation between the effects of LSD on each of these 
domains and on cognitive bizarreness.  
 
There is evidence that hallucinatory effects of psychedelics are mediated by serotonin 2A (5-
HT2A) receptor stimulation in the brain (Nichols 2004, Vollenweider et al. 1998). However, 
LSD has high affinity and agonist activity at 5-HT2A/C, 5-HT1A/B, 5-HT6, 5-HT7 and 
dopamine D2, D1 receptors (Gregorio et al. 2016, Halberstadt and Geyer 2011, Passie et al. 
2008, Marona-Lewicka and Nichols 2007, Marona-Lewicka et al. 2005, Nichols 2004, 
Giacomelli et al. 1998), and no previous study has investigated the specific receptor 
contributions to the cognitive effects of LSD in humans. Therefore, a third aim of this study 
was to investigate whether stimulation of the 5-HT2A receptor mediates the effects of LSD on 
cognitive bizarreness. To this end, we combined pharmacological manipulation (LSD) and the 
selective 5-HT2A receptor antagonist ketanserin (Leysen et al. 1982). Pre-treatment with 
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ketanserin reverses symptoms induced by the LSD-like psychedelic psilocybin in healthy 
subjects (Kometer et al. 2013, Quednow et al. 2012, Vollenweider et al. 1998). Using a 
double-blind, within-subjects study design, we systematically compared the post-peak effects 
of LSD, placebo and LSD after pre-treatment with ketanserin on cognitive bizarreness during 
a guided mental imagery task and in relation to the effects on subjective experience. 
 
Method  
 
Participants 
 
Twenty-five healthy subjects were recruited through an advertisement placed on the web 
platform of the University of Zurich. The Mini-International Neuropsychiatric Interview 
(Sheehan et al. 1998), the DSM-IV self-rating questionnaire for Axis-II personality disorders 
(Wittchen and Fydrich 1997) and the Hopkins Symptom Checklist (Franke and Derogatis 
1995) were used to exclude individuals with present or previous psychiatric disorders or a 
history of major psychiatric disorders in first-degree relatives. Verbal intelligence quotient 
was assessed using the multiple-choice vocabulary intelligence test (MWT-B) (Merz et al. 
1975). Subjects were healthy according to medical history, physical examination, routine 
blood analysis, electrocardiography and urine tests for drug use and pregnancy. Demographic 
characteristics of the study sample and lifetime use of illicit drugs are shown in Tables 1 and 
2, respectively. Of the 25 subjects, 9 (36%) reported prior experience with classic 
psychedelics. Cannabis had the highest prevalence of lifetime drug use, and the prevalence in 
our study sample (76%) was higher than the lifetime prevalence in a comparable population 
of Swiss students (59%) (Dammann et al. 2014). Subjects were required to abstain from the 
use of any prescription or illicit drug for a minimum of 2 weeks prior to the first test day and 
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for the duration of the entire study, and to abstain from drinking alcohol for at least 24 h prior 
to each test day. Six subjects were light cigarette smokers (<5 cigarettes/d) and were told to 
maintain their usual smoking habits but not to smoke cigarettes during the sessions. Urine 
tests and self-report questionnaires were used to verify the absence of drug and alcohol use 
and pregnancy on the screening visit and each experimental visit before drug administration. 
Urine tests of all subjects included in the study were negative. No alcohol test was performed.  
 
Study design 
 
Subjects participated in a double-blind, placebo-controlled, within-subjects, crossover design 
that involved three experimental sessions performed in a balanced order. The between-session 
interval was at least 2 weeks. The test sessions began at 7:45 AM. At 8:00 AM, subjects 
received pre-treatment and at 9:00 AM they received treatment. The pre-treatment/treatment 
combinations were as follows: placebo (179 mg of mannitol and 1 mg of aerosil orally) + 
LSD (100 mcg orally), ketanserin (40 mg orally) + LSD (100 mcg orally) and placebo + 
placebo. These are referred to as LSD, Ket+LSD and Pla conditions, respectively.  
 
Plasma concentration of LSD peaks 1.5 h (range, 0.5–4 h) after administration and has a half-
life of 3.6 h, slower elimination after 12 h and a terminal half-life of 8.9 h (Dolder et al. 
2015). After a single oral dose of 40 mg ketanserin, plasma concentration peaks after 1.1 h 
and has a relatively long elimination half-life of 29.2 h (Persson et al. 1987). The time delay 
between pre-treatment and treatment was 1 h, to ensure maximal 5-HT2A receptor occupancy 
(Ettrup et al. 2014). A single 40 mg dose of ketanserin taken orally represents a regular 
therapeutic dose and completely blocks 5-HT2A receptor-induced alterations in states of 
Kraehenmann et al. 
9 
 
consciousness of healthy subjects (Kometer et al. 2013, Quednow et al. 2012, Vollenweider et 
al. 1998).  
 
A standardised lunch was served at 1:00 PM. The mental imagery task was performed at 4:00 
PM, 7 h after drug treatment. This is during the descending phase of the acute effects of LSD 
(Dolder et al. 2015). This had the disadvantage that the effects of LSD were not evaluated 
during drug peak, but had the advantage that subjects could engage in a verbal dialogue, 
which was a requirement for the imagery task and which would have been very difficult 
during drug peak, where people often show reduced vigilance, impoverished speech and 
reluctance to engage in verbal communication despite having intense inner experiences 
(Johnson et al. 2008). The current study was a small part of a larger neuroimaging study 
(Preller et al. 2017), and the design of the larger study dictated that the mental imagery task be 
performed at 4:00 PM.  
 
A standardised dinner was served at 6:00 PM. At approximately 9:00 PM, about 12 h after 
treatment and therefore after the acute effects of LSD had subsided (Dolder et al. 2015), 
subjects were discharged into the custody of a family member or close friend.  
 
All subjects provided written informed consent prior to their inclusion in the study and were 
paid for their participation. The study was conducted in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and International Conference on Harmonization 
Guidelines in Good Clinical Practice and was approved by the Ethics Committee of the 
Canton of Zurich, Switzerland and the Swiss Agency for Therapeutic Products (Swissmedic). 
The administration of LSD to healthy subjects was authorised by the Swiss Federal Office for 
Public Health, Bern, Switzerland. 
Kraehenmann et al. 
10 
 
  
Study drugs 
 
Gelatine capsules that contained 100 mcg of LSD (d-LSD hydrate; Lipomed AG, Arlesheim, 
Switzerland) with a high purity (> 99%, high-performance liquid chromatography) (Dolder et 
al. 2015) and identical capsules that contained ketanserin (40 mg of Sufrexal®; Janssen-Cilag, 
Zug, Switzerland) or placebo (179 mg of mannitol and 1 mg of aerosil; Hospital Pharmacy, 
Canton Hospital, Lucerne, Switzerland) were administered in single oral doses. 
 
Guided mental imagery task 
 
The guided mental imagery task followed the standardised guided affective imagery 
procedure, a systematic imagery method for analytically oriented psychotherapy described by 
Leuner (1969). The task was performed in a quiet, slightly dimmed room. Subjects lay on a 
couch in a comfortable position with their eyes closed, and were instructed to focus their 
attention on their inner experience. After a brief instruction to relax, subjects were asked to 
imagine a motif (scene), for example, a meadow, any meadow that came to their mind. No 
further instructions were given; everything was left as open and as unstructured as possible so 
that the subjects could develop their own images and actions, projected onto the initial motif.  
 
Throughout the task, the guide remained in a loose form of dialogue with the subjects to keep 
himself informed of the development of the subjects’ imagery, and enabling him to slow 
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down the process and have the subjects delve more deeply into their imagery experience.
1
 To 
minimise the influence of the guide on the descriptions given by the subjects, open-ended, 
standardised questions were asked throughout. Present tense was used to focus the imagery 
experience on the here-and-now. Questions were only used to keep the imagery process going 
and to explore the imaginary world with all senses (e.g., “What are you doing?”, “What do 
you see/hear/smell/taste/feel?”, “Is there anything you are tempted to do right now?”, “How 
do you feel now?”, “Please describe”). Whenever possible, explicit verbal input from the 
guide was kept to a minimum and replaced by confirming fillers (e.g., “mhm”) or encouraging 
words (“keep going”). During the imagery task, no interpretations or comments on the 
imagery content were given. The guide was trained by the Swiss Association for Guided 
Affective Imagery, Berne (www.sagkb.ch).  
 
The motif used to begin the imagery task was a meadow in session one, a creek in session two 
and a house in session three. These were selected from the five basic motifs recommended by 
Leuner (1969) for imagery novices.  
 
The guided mental imagery task lasted 30 min. Verbal imagery reports from the subjects were 
audio recorded and later transcribed, yielding a total data set of 75 imagery reports. Most 
study subjects were naïve to mental imagery, and all subjects were familiarised with the task 
beforehand in a separate pre-investigation visit using a flower as the motif. All subjects could 
spontaneously engage in mental imagery.  
 
Outcome measures 
                                                     
1
 As this meditative state progresses, subjects experience a “quasi-reality” with its 
concomitant feelings and associated affects, which was termed “catathymic imagery” by 
Leuner (1969). 
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State of consciousness 
 
Subjective state of consciousness was evaluated using the five-dimensional Altered State of 
Consciousness (5D-ASC) questionnaire (Dittrich 1996). The 5D-ASC uses a visual analogue 
scale (VAS) to evaluate aetiology-independent alterations in consciousness, including 
changes in perception, mood, cognition and experience of self and environment. Subjective 
state of consciousness was quantified using five lower-order scales: elementary imagery 
(visual hallucinations of regular patterns, colours or light flashes), complex imagery (visual 
hallucinations of scenes and pictures), euphoric mood (positive affect and mania-like 
experiences), loss of self-boundaries and cognitive control (alterations in the experience of the 
self and body such as diminished subject-object and inner-outer dualities, and impaired 
control of thinking and volition) and changed meaning of percepts (increased attribution of 
personal meaning to environmental stimuli).   
 
Subjects completed a 45-item short version of the 5D-ASC at several time points (T1 = 180 
min, T2 = 270 min and T3 = 390 min after drug treatment). At T4 (720 min after drug 
treatment), after acute drug effects had receded, participants completed the 94-item full 
version of the 5D-ASC and were instructed to retrospectively rate the overall peak of their 
subjective experiences across the session. The mental imagery task was performed close to 
T3, at 420 min after drug treatment; therefore, the 5D-ASC short version completed at T3 was 
used to quantify subjective state of consciousness. The 5D-ASC full version completed at T4 
was not used as this retrospectively measured the state of consciousness during the drug peak, 
and the mental imagery task was performed during the descending phase of the subjective 
LSD effects (Dolder et al. 2015). 
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Intensity of drug effects  
The intensity of drug effects was evaluated using the global 5D-ASC (G-ASC) score. This is 
the average score of all 45 items in the short version of the 5D-ASC. The G-ASC for the full 
version of the 5D-ASC was calculated as the average score of the 45 items that appear in the 
short version. The G-ASC score at time points T1, T2, T3, and T4 was used to indicate the 
time course of drug effects across the session. The G-ASC score at time point T3 was used to 
indicate the intensity of drug effects at the time of the mental imagery task. In the LSD 
condition, the G-ASC score at time point T3 was also expressed as a percentage of the 5D-
ASC score at time point T4, to indicate the intensity of LSD effects at the time of the mental 
imagery task relative to the retrospectively rated peak drug effects.   
 
Mental imagery experience 
After completion of the mental imagery task, subjects retrospectively rated their mental 
imagery experience on VASs for visual vividness, emotional arousal, positive emotions, 
negative emotions, insight and relaxation. Each VAS was presented as a 100 mm horizontal 
line marked with “not at all” on the left and “extremely” on the right. 
 
Cognitive bizarreness of mental imagery reports 
 
Cognitive bizarreness of mental imagery reports was evaluated using an adapted version of 
Hobson’s two-stage scoring system for measuring cognitive bizarreness (Hobson 2009). This 
is a reliable and validated set of criteria that was used in previous studies of REM dream 
reports (Scarone et al. 2008, Williams et al. 1992). The scoring system is described in Table 
3. Each identified bizarre item was assigned a single main category (plot, cognition or feeling 
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state) and a combination of subcategories (e.g., discontinuity and incongruity). For plot and 
cognition, the uncertainty subcategory (A3 and B3, respectively) was combined into a single 
subcategory (A3/B3) because judges could not determine from the transcribed imagery 
reports whether the uncertainty arose as the subject reported his or her experience or was an 
inherent property of an imagined scenario.  
 
Imagery reports were scored by two external judges who were blind to drug condition. The 
judges independently scored the same 15 imagery reports (three reports per subject from a 
random sample of five subjects). Inter-rater reliability was quantified using intra-class 
correlation coefficient, and was 0.95. Each judge then randomly selected one-half of the 
remaining 60 imagery reports, and independently scored these 30 imagery reports.  
 
For each subject and each drug condition, bizarreness density (BD) was quantified for each 
category (plot, cognition and feeling state) and subcategory, respectively, by dividing the 
number of bizarre items in the report in that category and subcategory, respectively by the 
word count of the report. This was carried out to correct for differences in length of reports. 
Total BD was calculated by dividing the total number of bizarre items in the report (i.e., 
number of bizarre items in all categories) by the word count of the report. The mean (SD) 
number of words in the reports was 4353 (793), 3979 (851) and 4112 (893) for LSD, 
Ket+LSD and Pla conditions, respectively. 
 
Statistical analysis 
 
All statistical analyses were conducted using IBM SPSS Statistics 23 software (IBM, 
Chicago, Illinois, USA). 
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State of consciousness 
 
The 45-item 5D-ASC score at time point T3 was analysed using a repeated-measures analysis 
of variance (ANOVA) with drug (LSD, Ket+LSD and Pla) and scale (elementary imagery, 
complex imagery, euphoric mood, loss of self-boundaries and cognitive control, and changed 
meaning of percepts) as the within-subjects factors. Significant main effects or interactions in 
the ANOVA were followed by Bonferroni-corrected post-hoc pairwise comparisons with a 
significance level of p < 0.05 (two-tailed test).  
 
Intensity of drug effects  
 
The G-ASC score was analysed using a repeated-measures ANOVA with drug (LSD, 
Ket+LSD and Pla) and time point (T1, T2, T3, and T4) as the within-subjects factors.  
 
Mental imagery experience 
 
VAS scores for mental imagery experience were analysed using a repeated-measures 
ANOVA with drug (LSD, Ket+LSD and Pla) and scale (visual vividness, emotional arousal, 
positive emotions, negative emotions, insight and relaxation) as the within-subjects factors.  
 
Cognitive bizarreness of mental imagery reports 
 
BD was analysed using a repeated-measures ANOVA with drug (LSD, Ket+LSD and Pla) 
and bizarreness category (plot, cognition and feeling state) as the within-subjects factors, and 
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a separate repeated-measures ANOVA with drug (LSD, Ket+LSD and Pla) and bizarreness 
subcategory (plot discontinuity, plot incongruity, plot/cognition uncertainty, cognition 
discontinuity, cognition incongruity, feeling state discontinuity, feeling state incongruity and 
feeling state uncertainty) as the within-subjects factors.  
 
Relations between cognitive bizarreness, state of consciousness and mental imagery 
experience  
 
The LSD-induced change in cognitive bizarreness, state of consciousness and mental imagery 
experience was quantified using the change in total BD, 5D-ASC scale scores and mental 
imagery experience VAS scores between the LSD and Pla drug conditions (ΔBD, Δ5D-ASC 
and ΔVAS, respectively). Pearson multiple correlation was used to quantify the relations 
between these variables. 
 
A multiple linear regression analysis with removal with ΔBD as the dependent variable and 
Δ5D-ASC as predictor variables was used to further examine whether the LSD-induced 
change in total BD was associated with the LSD-induced change in state of consciousness. 
Collinearity tests, residual tests and diagnostic plots were used to detect outliers and to 
ascertain that regression modelling assumptions were met.  
 
 
Results 
 
State of consciousness  
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At the time of the mental imagery task, LSD still produced marked alterations in state of 
consciousness, as indicated by a significant main effect of drug, F(1.00, 24.03) = 27.86, p < 
0.001, partial η2 = 0.54, in a repeated-measures (drug × scale) ANOVA on 5D-ASC score at 
T3. There was also a significant main effect of scale, F(4.00, 63.70) = 8.40, p < 0.001, partial 
η2 = 0.26, and a significant drug × scale interaction, F(8.00, 68.44) = 7.54, p < 0.001, partial 
η2 = 0.24. Bonferroni-corrected post-hoc pairwise comparisons revealed a greater score on all 
five 5D-ASC scales in the LSD condition than in the Pla and Ket+LSD conditions (all p < 
0.05). Scores did not differ between the Pla and Ket+LSD conditions for any 5D-ASC scale 
(all p = n.s.), indicating that ketanserin pre-treatment completely blocked all LSD-induced 
effects (Figure 1a). 
 
[Insert Figure 1 about here] 
 
Intensity of drug effects  
 
Effects of LSD were apparent at each time point during the session, as indicated by a 
significant main effect of drug, F(1.00, 24.12) = 61.52, p < 0.001, partial η2 = 0.72, in a 
repeated-measures (drug × time) ANOVA of G-ASC score. There was also a significant main 
effect of time, F(1.93, 46.39) = 34.80, p < 0.001, partial η2 = 0.59, and a significant drug × 
time interaction, F(2.07, 49.56) = 27.59, p < 0.001, partial η2 = 0.54. Bonferroni-corrected 
post-hoc pairwise comparisons revealed greater G-ASC score at all four time points in the 
LSD condition than in the Pla and Ket+LSD conditions (all p < 0.001). G-ASC score did not 
differ between the Pla and Ket+LSD conditions for any 5D-ASC scale (all p = n.s.), indicating 
that ketanserin pre-treatment completely blocked all LSD-induced effects (Figure 1b).  
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In the LSD condition, the mean (SD) G-ASC score at the time of the mental imagery task and 
during drug peak was 23.78% (24.25) and 37.95% (21.89), respectively. At the time of the 
mental imagery task, the relative intensity of LSD effects was 62.6% of the peak. 
 
Mental imagery experience 
 
LSD significantly modulated subjective mental imagery experience, as indicated by a 
significant main effect of drug, F(2, 48) = 8.57, p < 0.001, partial η2 = 0.26, in a repeated-
measures (drug × scale) ANOVA of the retrospectively administered VAS for mental imagery 
experience. The ANOVA further revealed a significant main effect of scale, F(2.86, 68.71) = 
55.23, p < 0.001, partial η2 = 0.70, and a significant drug × scale interaction, F(5.58, 133.86) 
= 3.21, p = 0.007, partial η2 = 0.12. Bonferroni-corrected post-hoc pairwise comparisons 
revealed greater VAS score on the vividness and arousal scales in the LSD condition than in 
the Pla condition and on the vividness scale in the LSD condition than in the Ket+LSD 
condition (all p < 0.05). VAS score did not differ between the Pla and Ket+LSD conditions 
for any VAS scale (all p = n.s.), indicating that ketanserin pre-treatment completely blocked 
all LSD-induced effects (Figure 1c). 
 
Cognitive bizarreness of mental imagery reports 
 
LSD significantly increased cognitive bizarreness of mental imagery reports, as indicated by a 
significant main effect of drug, F(1.070, 25.60) = 33.57, p < 0.001, partial η2 = 0.58, in a 
repeated-measures (drug × category) ANOVA of BD. Bonferroni-corrected post-hoc 
comparisons on this main effect revealed significantly greater BD in the LSD condition than 
in the Pla and Ket+LSD conditions (all p < 0.001). BD did not differ between the Pla and 
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Ket+LSD conditions (all p = n.s.), indicating that ketanserin pre-treatment completely blocked 
the effect of LSD (Figure 2a). The ANOVA further revealed a significant main effect of 
category, F(1.15, 27.65) = 24.31, p < 0.001, partial η2 = 0.50, and a significant interaction of 
drug × category, F(1.24, 29.71) = 223.14, p < 0.001, partial η2 = 0.41. Bonferroni-corrected 
post-hoc pairwise comparisons on this interaction revealed greater BD for two of the three 
categories in the LSD condition than in the Pla and Ket+LSD conditions (all p < 0.05). BD for 
the feeling state category did not differ across drug conditions (all p = n.s.). BD did not differ 
between the Pla and Ket+LSD conditions for any category (all p = n.s.), indicating that 
ketanserin pre-treatment completely blocked all LSD-induced effects (Figure 2a).  
 
A separate repeated-measures (drug × subcategory) ANOVA of BD revealed a significant 
main effect of drug, F(1.06, 25.46) = 37.00, p < 0.001, partial η2 = 0.61. The ANOVA further 
revealed a significant main effect of subcategory, F(1.74, 41.67) = 19.19, p < 0.001, partial η2 
= 0.44, and a significant drug × subcategory interaction, F(2.14, 51.31) = 18.87, p < 0.001, 
partial η2 = 0.44. Bonferroni-corrected post-hoc pairwise comparisons revealed greater BD on 
four of the eight subcategories in the LSD condition than in the Pla and Ket+LSD conditions 
(all p < 0.05). BD did not differ between the Pla and Ket+LSD conditions for any subcategory 
(all p = n.s.), indicating that ketanserin pre-treatment completely blocked all LSD-induced 
effects (Figure 2b). 
 
[Insert Figure 2 about here] 
 
Relations between cognitive bizarreness, state of consciousness and mental imagery 
experience  
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There was a significant positive correlation between LSD-induced increase in total BD and 
LSD-induced increase in 5D-ASC score for the loss of self-boundaries and cognitive control 
scale (r = 0.44, N = 25, p < 0.05, uncorrected) (Table 4 and Figure 3). There was also a 
trend-level correlation between LSD-induced increase in total BD and LSD-induced increase 
in 5D-ASC score for the euphoric mood scale (p = 0.05, uncorrected) and emotional arousal 
VAS score (p = 0.08, uncorrected). A multiple linear regression analysis was used to develop 
a model to predict LSD-induced increase in total BD from LSD-induced increase in 5D-ASC 
scale scores. The loss of self-boundaries and cognitive control 5D-ASC scale was the only 
predictor that had a significant (p < 0.05) partial effect in the full model. The model accounted 
for 19% of the variance in LSD-induced increase in total BD, F(1, 23) = 5.50, p = 0.03, 
adjusted R
2
 = 0.19. 
[Insert Figure 3 about here] 
 
 
Discussion 
 
In this psychopharmacological study, we provide quantitative evidence that LSD produces 
dreamlike imagery in healthy humans when awake. Specifically, we conclusively show that 
LSD, in comparison with placebo, increased cognitive bizarreness, a formal measure of REM 
dream mentation (Hobson 2009) (Figure 2). Furthermore, we show that the dreamlike effect 
of LSD was mediated by brain 5-HT2A receptor stimulation (Figure 2) and was related to 
LSD-induced subjective loss of self-boundaries and cognitive control (Figure 3 and Table 4). 
The findings of this study confirm the long-held view that psychedelics induce dreamlike 
states of consciousness (Carhart-Harris and Nutt 2014, Schmid et al. 2015, Tagliazucchi et al. 
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2014, Studerus et al. 2011, Hobson 2001, Fischman 1983, Jacobs 1978) and provide a deeper 
understanding of the link between the psychedelic state of consciousness and dreaming. 
 
Cognitive bizarreness and sense of self 
 
Several effects of LSD could increase cognitive bizarreness. One is LSD-induced disturbance 
of the basic sense of self, also known as depersonalisation. Similar to what happens during 
dreaming (Kahn 2013), this alters fundamental structures of consciousness, i.e., mental 
framework and perspectives on space, time, causality and selfhood. Our results show that the 
LSD-induced increase in the cognitive bizarreness of mental imagery reports was related to 
the LSD-induced loss of self-boundaries and cognitive control (Figure 3 and Table 4). This 
finding is in accordance with a recent functional magnetic resonance imaging study (Preller et 
al. 2017) that used a music paradigm to investigate the effects of LSD on the processing of 
personal meaning. Preller et al. reported that LSD increased behavioural measures of meaning 
attribution as well as activity in cortical midline regions and the ventrolateral prefrontal cortex 
in response to previously meaningless music stimuli. They concluded that LSD alters meaning 
attribution by increasing the activity of brain areas that are typically involved in self 
processing.  
 
Our finding is also in line with studies that used the LSD-like 5-HT2A/1A receptor agonist 
psilocybin and showed that psilocybin-induced cognitive symptoms such as disorganised 
thinking were secondary to psilocybin-induced self-disturbance (Vollenweider and Geyer 
2001, Vollenweider et al. 1997). A recent study (Lebedev et al. 2015) found that individual 
variability of psilocybin-induced psychedelic symptoms was best explained by a common 
factor that included vivid dreamlike imagery, loss of self-boundaries and fear of losing control 
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over thought processes. Moreover, there is evidence that bizarreness in REM dreams of 
normal subjects (Fosse et al. 2004) and in waking thoughts and dreams of schizophrenic 
patients (Rasmussen and Parnas 2015, Sass and Byrom 2015, Scarone et al. 2008, Limosani et 
al. 2011) is closely related to disturbed sense of self, and there is qualitative evidence that 
many bizarre features of both psychedelic imagery and dreams can be traced back to loss of 
self-boundaries and cognitive control (Pines 1976, Leuner 1968, Savage 1955, Abramson et 
al. 1955). For example, one subject in the present study described loss of self-boundaries and 
cognitive control, and how closely this was related to bizarre imagery in the LSD condition as 
follows: “I merged with the environment. I became one with all. It made me float around, and 
I no longer had a will to decide where I should go next. I felt that everything was happening 
without my volition. At one moment, everything wound around me, like a plant. And then I 
went into the core of the plant, and suddenly, I somehow emerged within an air bubble that 
was spat out of a volcano. I was me, but somehow also not me. And then, I was flowing down 
the volcano as a lava stream.” 
 
Cognitive bizarreness and basic visual processing   
 
A second effect of LSD that could increase cognitive bizarreness is changes in basic visual 
processes. This is supported by a recent neuroimaging study (Carhart-Harris et al. 2016), 
which showed that LSD-induced simple and complex hallucinations were closely related to 
LSD-induced activation of the primary visual cortex. This is further supported by 
mathematical modelling (Bressloff et al. 2002, Ermentrout and Cowan 1979) and behavioural 
(Baggott et al. 2010) and neuroimaging (Roseman et al. 2016, Araujo et al. 2012) studies 
showing that psychedelic-induced excitation of the primary visual cortex may facilitate 
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spontaneous formation of retinotopically organised geometric hallucinations, which in turn 
could progress to more complex scenic hallucinations by spreading up the visual hierarchy.  
 
However, our results clearly support the conclusion of other authors (Family et al. 2016, 
Fischer and Landon 1972, Weintraub et al. 1959, Savage 1955) that it is not the interaction of 
LSD with basic visual processing, but rather LSD-induced higher-level alterations of self and 
cognition, that increase cognitive bizarreness. First, the LSD-induced increase in cognitive 
bizarreness was not related to a change in the elementary and complex imagery scale of the 
5D-ASC, nor to VAS score of the visual vividness of mental imagery (Table 4). Second, the 
effects of LSD on cognitive bizarreness were not evenly distributed across the bizarreness 
subcategories (Figure 2), as would be expected from a purely bottom-up account of cognitive 
bizarreness based on random visual noise. Rather, they were loaded heavily on the plot 
category, and much less on the cognition and feeling state categories. This indicates that, 
despite unrealistic content in terms of plot, character, objects or actions, mental imagery 
reports in the LSD condition still contained a narrative structure and a relatively coherent 
unfolding of imaginary events over time. This narrative-thematic constancy is also 
characteristic of dreaming, where it is known as single-mindedness (Rechtschaffen 1978). 
During LSD imagery, for example, one study subject saw a mouldered shipwreck on the 
seashore. He unlocked and entered a dungeon inside the ship’s hull. There, he found the bones 
of a dead pirate, scattered on the wooden floor. Next to the pirate, there was a bottle of rum, 
gold and jewellery. The subject then realised, for the first time and with a certain degree of 
emotional involvement, that he had been pursuing ambitious life goals such as career-building 
and money-making, but with consequences of social neglect and chronic feelings of 
loneliness.  
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Cognitive bizarreness and creative thinking 
 
A third effect of LSD that could increase cognitive bizarreness is an increase in creative, or 
divergent, nonlinear thinking, which is defined as a thought process where many responses to 
a single question or problem are generated, and where the responses are often novel or lead to 
a broader perspective than in normal thought (Guilford 1967). Although we did not directly 
investigate the effects of LSD on creative thinking, during the LSD condition subjects 
consistently reported that they experienced their imagery as “very dynamic, rapidly changing, 
fugitive, enormously varied”, “less inhibited by logical constraints and necessity to make 
sense” and “spontaneously, effortlessly, evolving more naturally.” Importantly, many subjects 
retrospectively reported that imaginary objects and scenes were like a condensation and 
recombination of multiple memory fragments, allowing them to see things under novel 
perspectives and relations. This latter notion is supported by the result that discontinuous, 
incongruent imaginary content in terms of plot, character, objects or actions accounted for the 
largest component of cognitive bizarreness during LSD (Figure 2). Furthermore, this is 
supported by a growing body of literature (Sweat et al. 2016, Baggott 2015, Sessa 2008, 
Leuner 1973) indicating that psychedelics induce a state of broadened consciousness that is 
associated with a different cognitive style, including facilitated access to remote semantic 
associations (Family et al. 2016, Spitzer et al. 1996, Rittenhouse et al. 1994); cross-modal 
fusion between sensory modalities (synaesthesia), perception and feeling (physiognomic 
perception) and imagery and perception (eidetic imagery) (Terhune et al. 2016, Sinke et al. 
2012, Glicksohn 1992); thinking in metaphors and symbols (Lakoff 1993, Martindale and 
Fischer 1977, Landon and Fischer 1970); enhanced problem solving capabilities (Frecska et 
al. 2012, Sio et al. 2013, Ullrich et al. 2004); and increased topographically long-range 
neuronal connectivity in the brain (Achermann et al. 2016, Petri et al. 2014, Massimini et al. 
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2010). Taken together, these findings suggest that creative thinking may be an important 
mechanism behind cognitive bizarreness, where there is increased binding of logically 
incompatible, but associatively remotely connected, features into new phenomenological 
Gestalts (Rittenhouse et al. 1994). This hypothesis should be tested in future studies by 
concurrently assessing LSD-induced changes in cognitive bizarreness and measures of 
creative thinking in the same subjects. 
 
Cognitive bizarreness and the 5-HT2A receptor 
 
LSD-induced effects on cognitive bizarreness could be related to several LSD-induced 
effects, including loss of self-boundaries and cognitive control, and enhancement of creative 
thinking. However, our results showed that all LSD-induced effects, including effects on 
subjective reports of state of consciousness (5D-ASC score) and mental imagery experience 
(VAS scores; Figure 1) and on the cognitive bizarreness of mental imagery (Figure 2), were 
fully blocked by the 5-HT2A receptor antagonist ketanserin. This shows that stimulation of 
the 5-HT2A receptor is a key mechanism of action mediating both the LSD-induced changes 
in subjective experience and the dreamlike effects of LSD.  
 
This finding is in line with previous animal (Halberstadt and Geyer 2010, González-Maeso et 
al. 2007) and human (Valle et al. 2016, Kometer et al. 2013, Quednow et al. 2012, Carter et 
al. 2005) studies showing that psychedelic effects can be reversed by 5-HT2A inverse 
agonists or antagonists, and that 5-HT2A receptor antagonism is key to the antipsychotic 
properties of multi-receptor acting atypical antipsychotic drugs such as clozapine (Meltzer et 
al. 2009, Meltzer et al. 2003). This finding is also in line with previous human studies that 
highlighted the importance of 5-HT receptor involvement in the generation of complex visual 
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hallucinations in Parkinson’s disease (Ballanger et al. 2010) and in the sporadic dream-
enhancing effects of selective serotonin-reuptake inhibitors (Pace-Schott 2008, Pace-Schott et 
al. 2001).  
 
However, the current result that dreamlike effects of LSD were blocked by ketanserin is 
somewhat surprising given that LSD also stimulates dopamine D2 and D1 receptors (Gregorio 
et al. 2016, Halberstadt and Geyer 2011, Passie et al. 2008, Marona-Lewicka and Nichols 
2007, Marona-Lewicka et al. 2005, Nichols 2004, Giacomelli et al. 1998), that activation of 
dopamine receptors in mesolimbic and mesocortical systems is a crucial receptor mechanism 
in the generation of dream imagery (Solms 2000) and the visual hallucinations of 
schizophrenic patients (Gottesmann 2006) and that dopaminergic agonists such as levodopa 
can induce vivid dreaming (Thompson and Pierce 1999). Furthermore, animal studies 
(Halberstadt 2015, Celada et al. 2004, Amargós-Bosch et al. 2004, Krebs-Thomson and Geyer 
1998, Schreiber et al. 1995, Araneda and Andrade 1991) suggest that 5-HT1A receptor 
stimulation produces the opposite behaviours to the 5-HT2A receptor-mediated behaviours 
induced by psychedelics. In humans, the non-hallucinogenic and selective 5-HT1A receptor 
agonist buspirone reduced psilocybin-induced simple and complex hallucinations (Pokorny et 
al. 2016), and pre-treatment with the 5-HT1A antagonist pindolol enhanced the psychedelic 
effects of N,N-Dimethyltryptamine (Strassman 1995). Moreover, 5-HT1A receptor 
stimulation may suppress REM sleep (Driver et al. 1995, Gillin et al. 1994).  
 
Therefore, although the present results strongly indicate that the subjective and dreamlike 
effects of LSD are predominantly mediated by 5-HT2A receptor stimulation, future studies 
should specifically assess the differential contributions of D2/D1 and 5-HT1A receptors, e.g., 
by using selective receptor antagonists such as haloperidol (Vollenweider et al. 1998) or 
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pindolol (Nichols 2004), or by using non-hallucinogenic 5-HT2A receptor agonists such as 
lisuride (González-Maeso et al. 2007) or 2,5-dimethoxy-4-ethylamphetamine (DOET) 
(Snyder et al. 1969). Investigating the effects of the non-hallucinogenic 5-HT2A receptor 
agonist DOET on cognitive bizarreness would be a particularly intriguing approach because, 
in human studies, DOET did not produce visual hallucinations but increased associative 
thinking and induced an altered sense of self (Snyder et al. 1971, Weingartner et al. 1970). 
 
Limitations  
 
Most of the study subjects were naïve to LSD. This might have impaired their ability to 
exercise cognitive control over the imagery experience in the LSD condition. In future 
studies, it might be interesting to assess individual predisposition to navigate through 
psychedelic imagery or to increase these cognitive capabilities via, for example, mindfulness 
training (Stumbrys et al. 2015). A further limitation is that the effects of LSD on imagery 
could have been due, at least partially, to changes in language production (Family et al. 2016) 
or attention (Passie et al. 2008), which would have influenced directly the narrative 
description of imagery content rather than imagery mentation itself. Although the effects of 
LSD on imagery were not evenly distributed across the bizarreness subcategories - as would 
be expected from general effects on language production or attention - we cannot rule out this 
potential confound completely. Therefore, it would be informative to include a control task 
(such as a description of a video) in future studies to differentiate between narrative 
descriptions of mental imagery and narrative descriptions of visual imagery in relation to 
cognitive bizarreness. Finally, animal studies (Marona-Lewicka and Nichols 2007, Marona-
Lewicka et al. 2005) have shown that the behavioural effects of LSD occur in two temporal 
phases, with later effects being substantially mediated by D2 receptor stimulation. Therefore, 
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the lateness of the imagery task is a further limitation, because we cannot assume that late 
effects are merely a lesser version of early effects. 
 
Potential clinical implications 
 
Although psychedelic-induced visual hallucinations have been related to broadband decreases 
in electrophysiological oscillations, there are reports that oscillations in the gamma range are 
intact or even slightly increased during psychedelic states (Kometer et al. 2015, 
Muthukumaraswamy et al. 2013). Given that gamma range oscillations have been related to 
dream cognition (Llinás and Ribary 1993) and enhanced dream lucidity (Voss et al. 2014), 
which is the awareness during dreaming that one is dreaming and the capacity to wilfully 
influence some aspects of the dream actions, one might speculate that psychedelic dream 
states differ from normal night dreams in the degree of lucidity and gamma range oscillatory 
activity in frontotemporal regions of the brain. In fact, unlike during sleep, psychedelic states 
are not characterised by drowsiness and loss of awareness, but rather by an enhanced clarity 
and richness of consciousness (Leuner 1981). One might even speculate that the psychedelic-
specific combination of lucid consciousness with loss of self-boundaries and cognitive control 
might relax rigid thinking and let previously unrecognised, self-relevant images rise into 
consciousness (LaBerge and Rheingold 1991). This might be an important mechanism to 
facilitate psychological insight, a notion that is supported by early clinical studies in the fifties 
of the last century (Sandison and Whitelaw 1957, Frederking 1955, Savage 1955, Sandison 
1954, Sandison et al. 1954, 1954, Busch and Johnson 1950), when LSD was used as an aid in 
psychotherapeutic treatment of chronic psychiatric conditions. 
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Conclusions 
 
Using a standardised, formal measure of dreaming cognition in healthy subjects, we found 
that LSD produced mental imagery comparable to that reported in dreams, primarily via 
activation of the 5-HT2A receptor. Dreamlike effects of LSD were related to loss of self-
boundaries and cognitive control, but not to visual hallucinations. Future studies should 
further assess the contribution of specific subtypes of 5-HT and dopamine receptors to 
cognitive bizarreness. 
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Figure Legends 
Fig. 1 Subjective state of consciousness and mental imagery experience; a) State of consciousness 
at the time of the mental imagery task. The graph shows the score on each 5D-ASC scale at time 
point T3 in each drug condition. LSD increased the score on all five 5D-ASC scales. Ketanserin pre-
treatment completely blocked all LSD-induced effects (all p = n.s.); b) Intensity of drug effects 
across the experimental session. The graph shows G-ASC score at each time point in each drug 
condition. At T1-T3, G-ASC score represents the intensity of drug effects at those time points, 
whereas, at T4, the 5D-ASC was retrospectively rated and G-ASC score represents the drug peak 
effects. T3 was immediately prior to the mental imagery task. LSD increased the G-ASC at all time 
points, and G-ASC showed a typical nonlinear decline over time, as previously shown (Dolder et al. 
2015, Schmid et al. 2015, Passie et al. 2008). Ketanserin pre-treatment completely blocked all LSD-
induced effects (all p = n.s.); c) Mental imagery experience. The graph shows the VAS score for 
each aspect of mental imagery experience in each drug condition. LSD increased VAS score for visual 
vividness and emotional arousal. Ketanserin pre-treatment completely blocked all LSD-induced effects 
(all p = n.s.). Data are expressed as mean plus standard error in N = 25 subjects. Asterisks indicate 
significant differences between LSD and placebo conditions (*p < 0.05; **p < 0.001, Bonferroni-
corrected). 5D-ASC, Altered States of Consciousness; G-ASC, global 5D-ASC; VAS, visual analogue 
scale; Pla, placebo; Ket, ketanserin; LSD, lysergic acid diethylamide; T1 = 180 min, T2 = 270 min, T3 
= 390 min, T4 = 720 min after drug treatment. 
 
Fig. 2 Bizarreness density (BD) of guided mental imagery reports; a) Total BD and BD in each 
main category. The graph shows total BD and BD in each main category in each drug condition. LSD 
increased BD for the plot and cognition categories (both p < 0.001), but not BD for the feeling state 
category (p = n.s.). Ketanserin pre-treatment completely blocked all LSD-induced effects (all p = n.s.); 
b) BD in each subcategory. The graph shows BD in each subcategory in each drug condition. LSD 
increased BD for plot discontinuity, plot incongruity, plot/cognition uncertainty and cognition 
incongruity subcategories (all p < 0.05). Ketanserin pre-treatment completely blocked all LSD-
induced effects (all p = n.s.). Data are expressed as mean plus standard error in N = 25 subjects. 
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Asterisks indicate significant differences between LSD and placebo conditions (*p < 0.05; **p < 
0.001, Bonferroni-corrected). A1, plot discontinuity; A2, plot incongruity; A3/B3, plot/cognition 
uncertainty; B1, cognition discontinuity; B2, cognition incongruity; C1, feeling state discontinuity; 
C2, feeling state incongruity; C3, feeling state uncertainty; Pla, placebo; Ket, ketanserin; LSD, 
lysergic acid diethylamide. 
 
Fig. 3 Change in loss of self-boundaries and cognitive control was related to change in cognitive 
bizarreness of guided mental imagery reports. The scatter plot shows the relation between the LSD-
induced increase in score on the loss of self-boundaries and cognitive control scale of the 5D-ASC 
(difference between LSD and placebo drug conditions, x-axis) and the LSD-induced increase in total 
bizarreness density (BD) of mental imagery reports (difference between LSD and placebo drug 
conditions, y-axis) (r = 0.44, N = 25, p < 0.05, uncorrected).  
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Tables 
Table 1 Demographic characteristics of study sample (N = 25) 
Demographic Mean (SD)
a
 
Gender (male/female) 19/6 
Age (years) 25.3 (3.7) 
Education (n)  
 High-school diploma 1 
 University student 16 
 University degree 8 
Verbal intelligence quotient 108.4 (9.2) 
a
If not otherwise specified. 
 
Table 2 Lifetime use of illicit drugs reported by the study sample (N = 25) 
Illicit drug Number of subjects who reported a lifetime history 
of use; mean (SD) number of uses during last 
month (in subjects with lifetime use) 
Cannabis 19; 1.1 (2.1) 
MDMA
a
 7; 0 
Psilocybin 6; 0 
LSD
b
 3; 0 
Amphetamine 3; 0 
Cocaine 3; 0 
GHB
c
 3; 0 
LSA (Hawaiian baby woodrose)
d
 1; 0 
DMT
e
 1; 0 
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Ketamine 1; 0 
2C-E
f
 1; 0 
a
3,4-Methylenedioxymethamphetamine. 
b
Lysergic acid diethylamide. 
c
Gamma-hydroxybutyric acid. 
d
D-lysergic acid amide. 
e
N,N-Dimethyltryptamine. 
f
2,5-Dimethoxy-4-ethylphenethylamin. 
 
Table 3 Two-stage scoring system for cognitive bizarreness 
Code Definition 
Stage 1   Identifies items as bizarre if they are physically impossible or improbable  
A  Plot, characters, objects or action 
B  Thoughts of the subject or of imaginary character 
C  Feeling state of the subject or imaginary character 
 Stage 2  Then establishes the character of each item of bizarreness 
 1 Discontinuity (change of identity, time, place or features thereof) 
 2 Incongruity (mismatching features) 
 3 Uncertainty (explicit vagueness) 
 
 
 
Table 4 Correlations between LSD-induced increase in cognitive bizarreness, subjective state of consciousness and subjective mental imagery 
experience ratings 
Variables, T3
a
 1 
 
2 3 4 5 6 
 
7 8 9 10 11 12 
1. Total BDb              
2. Elementary imageryc 0.22            
3. Complex imageryc 0.32 0.85**           
4. Euphoric mood statec 0.40 0.71** 0.83**          
5. Loss of self-boundaries  
and cognitive control
c
 
0.44* 0.75** 0.86** 0.94**         
6. Changed meaning of 
percepts
c
 
0.33 0.73** 0.80** 0.90** 0.83**        
7. Visual vividnessd 0.05 0.37 0.27 0.40* 0.35 0.42*       
8. Emotional arousald -0.36 0.32 0.33 0.42* 0.37 0.45* 0.42*      
9. Positive emotionsd -0.29 0.15 0.20 0.09 0.02 0.24 0.61** 0.46*     
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Variables, T3
a
 1 
 
2 3 4 5 6 
 
7 8 9 10 11 12 
10. Negative emotionsd 0.18 -0.05 0.05 0.22 0.29 -0.06 -0.14 0.03 -0.49*    
11. Insightd 0.07 0.24 0.30 0.56** 0.55** 0.47* 0.40* 0.40* 0.14 0.14   
12. Relaxationd -0.11 0.19 0.07 -0.04 -0.03 0.22 0.22 0.10 0.56** -0.59** 0.11  
a
LSD-Pla change scores. 
b
Total bizarreness density in the mental imagery report. 
c
Subscale of the short version of the Altered State of 
Consciousness (5D-ASC) questionnaire completed at T3, 390 min after drug administration. 
d
Visual analogue scale rating of mental imagery 
experience. *p < 0.05, uncorrected. **p < 0.001, uncorrected. N = 25
 
